Figure 3
Celecoxib attenuated the systemic LPS-induced change in expression of DAT and α-synuclein (A), [ 3 H]DA uptake (B), and mitochondrial complex I enzymatic activity (C) in the rat brain. Aa, Western blotting of protein expression of DAT and α-synuclein in P6 rat brain. Ab, Expression of DAT (left panel of Ab) and α-synuclein (right panel of Ab) is presented as the percentage of expression in the control group (Saline + Vehicle). Systemic LPS exposure increased DAT and α-synuclein expression in P6 rat brain. Celecoxib treatment attenuated the LPS-induced increase in expression of DAT and α-synuclein in the P6 rats. B, Dopamine uptake was measured by total [3H]DA uptake into brain synaptosomes and [3H]DA uptake is presented as the percentage of data in the control group (Saline + Vehicle). LPS exposure increased [3H]DA uptake in P6 rat brain. Celecoxib attenuated the LPS-induced increase in total [3H]DA uptake in the P6 rats. C, LPS exposure reduced enzymatic activity of mitochondrial complex I in 24 hours after LPS injection. Celecoxib treatment attenuated the LPS-induced decrease in mitochondrial complex I activity in P6 rats. The results are expressed as the mean ± SEM of six animals in each group, and analyzed by one-way ANOVA. *P <0.05 represents a significant difference for the LPS + Vehicle group or LPS + Celecoxib group as compared with the Saline + Vehicle group. # P <0.05 represents a significant difference for the LPS + Celecoxib group as compared with the LPS + Vehicle group.